pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›tibulizumab
drug · antibody
save

tibulizumab

Phase 2updated 6mo ago
by $ZURA Zura Bio Ltd🔗 ChEMBL
Phase 2
community read0 votes

Antibody drug with a maximum clinical stage of Phase 2 3 (across all indications), with 2 investigational indications.

targets

Interleukin-17ATumor necrosis factor ligand superfamily member 13B

all catalysts(0)

nothing on the calendar yet

Trials studying tibulizumab

  • phase2Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)active not recruitingn=80
  • phase2Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defenseactive not recruitingn=225

News(4)

  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
    biopharma_dive · 5d ago
  • STAT+: Gene therapy’s long-debated cancer risk materializes
    For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…
    stat · 7d ago
  • Zura reports Phase 2 flop in painful skin disorder, stock nosedives
    A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fa…
    endpoints · 7d ago
  • Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
    Zura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa trial, prompting the biotech to end development in the indication while continuing studies in other settings.
    fiercebiotech · 8d ago
generic
tibulizumab
MOA
Interleukin 17A inhibitor; Tumor necrosis factor ligand superfamily member 13B inhibitor
indication
Hidradenitis Suppurativa
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?